Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
33%(2 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_3
1
13%
Ph phase_1
6
75%
Ph phase_2
1
13%

Phase Distribution

6

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
6(75.0%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(6)
Terminated(2)

Detailed Status

Completed6
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (75.0%)
Phase 21 (12.5%)
Phase 31 (12.5%)

Trials by Status

withdrawn113%
completed675%
terminated113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_3

Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

NCT01571284
completedphase_1

A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients

NCT00876044
terminatedphase_1

Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient

NCT01955629
completedphase_1

A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies

NCT01930552
withdrawnphase_2

Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer

NCT02085005
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT01571284Phase 3

Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Completed
NCT00876044Phase 1

A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients

Completed
NCT01955629Phase 1

Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient

Terminated
NCT01930552Phase 1

A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies

Completed
NCT02085005Phase 2

Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer

Withdrawn
NCT00545246Phase 1

A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients

Completed
NCT01148615Phase 1

A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors

Completed
NCT00479076Phase 1

A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8